Boston Scientific Revenue 2010-2024 | BSX
Boston Scientific annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Boston Scientific revenue for the quarter ending June 30, 2024 was $4.120B, a 14.48% increase year-over-year.
- Boston Scientific revenue for the twelve months ending June 30, 2024 was $15.228B, a 13.64% increase year-over-year.
- Boston Scientific annual revenue for 2023 was $14.24B, a 12.29% increase from 2022.
- Boston Scientific annual revenue for 2022 was $12.682B, a 6.68% increase from 2021.
- Boston Scientific annual revenue for 2021 was $11.888B, a 19.92% increase from 2020.
| Boston Scientific Annual Revenue (Millions of US $) |
|
|---|---|
| 2023 | $14,240 |
| 2022 | $12,682 |
| 2021 | $11,888 |
| 2020 | $9,913 |
| 2019 | $10,735 |
| 2018 | $9,823 |
| 2017 | $9,048 |
| 2016 | $8,386 |
| 2015 | $7,477 |
| 2014 | $7,380 |
| 2013 | $7,143 |
| 2012 | $7,249 |
| 2011 | $7,622 |
| 2010 | $7,806 |
| 2009 | $8,188 |
| Boston Scientific Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2024-06-30 | $4,120 |
| 2024-03-31 | $3,856 |
| 2023-12-31 | $3,725 |
| 2023-09-30 | $3,527 |
| 2023-06-30 | $3,599 |
| 2023-03-31 | $3,389 |
| 2022-12-31 | $3,242 |
| 2022-09-30 | $3,170 |
| 2022-06-30 | $3,244 |
| 2022-03-31 | $3,026 |
| 2021-12-31 | $3,127 |
| 2021-09-30 | $2,932 |
| 2021-06-30 | $3,077 |
| 2021-03-31 | $2,752 |
| 2020-12-31 | $2,708 |
| 2020-09-30 | $2,659 |
| 2020-06-30 | $2,003 |
| 2020-03-31 | $2,543 |
| 2019-12-31 | $2,904 |
| 2019-09-30 | $2,707 |
| 2019-06-30 | $2,631 |
| 2019-03-31 | $2,493 |
| 2018-12-31 | $2,561 |
| 2018-09-30 | $2,393 |
| 2018-06-30 | $2,490 |
| 2018-03-31 | $2,379 |
| 2017-12-31 | $2,409 |
| 2017-09-30 | $2,222 |
| 2017-06-30 | $2,257 |
| 2017-03-31 | $2,160 |
| 2016-12-31 | $2,191 |
| 2016-09-30 | $2,105 |
| 2016-06-30 | $2,126 |
| 2016-03-31 | $1,964 |
| 2015-12-31 | $1,978 |
| 2015-09-30 | $1,888 |
| 2015-06-30 | $1,843 |
| 2015-03-31 | $1,768 |
| 2014-12-31 | $1,887 |
| 2014-09-30 | $1,846 |
| 2014-06-30 | $1,873 |
| 2014-03-31 | $1,774 |
| 2013-12-31 | $1,838 |
| 2013-09-30 | $1,735 |
| 2013-06-30 | $1,809 |
| 2013-03-31 | $1,761 |
| 2012-12-31 | $1,820 |
| 2012-09-30 | $1,735 |
| 2012-06-30 | $1,828 |
| 2012-03-31 | $1,866 |
| 2011-12-31 | $1,848 |
| 2011-09-30 | $1,874 |
| 2011-06-30 | $1,975 |
| 2011-03-31 | $1,925 |
| 2010-12-31 | $2,002 |
| 2010-09-30 | $1,916 |
| 2010-06-30 | $1,928 |
| 2010-03-31 | $1,960 |
| 2009-12-31 | $2,079 |
| 2009-09-30 | $2,025 |
| 2009-06-30 | $2,074 |
| 2009-03-31 | $2,010 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $122.346B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.139B | 25.33 |
| Stryker (SYK) | United States | $137.702B | 32.18 |
| Medtronic (MDT) | Ireland | $114.719B | 17.07 |
| EssilorLuxottica (ESLOY) | France | $106.985B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.286B | 35.30 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.218B | 0.00 |
| ResMed (RMD) | United States | $35.640B | 31.38 |
| Koninklijke Philips (PHG) | Netherlands | $29.674B | 22.55 |
| Terumo (TRUMY) | Japan | $28.204B | 39.83 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.935B | 13.81 |
| Baxter (BAX) | United States | $19.749B | 13.39 |
| Insulet (PODD) | United States | $16.507B | 69.45 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.465B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.256B | 30.67 |
| Demant (WILYY) | Denmark | $8.667B | 0.00 |
| BellRing Brands (BRBR) | United States | $7.864B | 33.25 |
| Lantheus Holdings (LNTH) | United States | $7.251B | 17.41 |
| ICU Medical (ICUI) | United States | $4.262B | 40.67 |
| Haemonetics (HAE) | United States | $3.918B | 19.38 |
| Neogen (NEOG) | United States | $3.612B | 37.89 |
| TG Therapeutics (TGTX) | United States | $3.612B | 38.25 |
| GN Store Nord (GNNDY) | Denmark | $3.576B | 21.54 |
| Prestige Consumer Healthcare (PBH) | United States | $3.536B | 17.62 |
| Perrigo (PRGO) | Ireland | $3.496B | 11.05 |
| Envista Holdings (NVST) | United States | $3.310B | 17.66 |
| QuidelOrtho (QDEL) | United States | $2.970B | 18.72 |
| Agios Pharmaceuticals (AGIO) | United States | $2.734B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.220B | 37.25 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.109B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.029B | 54.07 |
| Warby Parker (WRBY) | United States | $1.620B | 0.00 |
| InMode (INMD) | Israel | $1.444B | 9.19 |
| AdaptHealth (AHCO) | United States | $1.385B | 10.00 |
| AtriCure (ATRC) | United States | $1.384B | 0.00 |
| Owens & Minor (OMI) | United States | $1.213B | 9.36 |
| Verano Holdings (VRNOF) | United States | $1.199B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.115B | 0.00 |
| Evolus (EOLS) | United States | $1.032B | 0.00 |
| PetIQ (PETQ) | United States | $0.919B | 23.29 |
| Phibro Animal Health (PAHC) | United States | $0.895B | 18.57 |
| National Vision Holdings (EYE) | United States | $0.852B | 27.10 |
| Cresco Labs (CRLBF) | United States | $0.820B | 0.00 |
| Surmodics (SRDX) | United States | $0.549B | 116.58 |
| Quanterix (QTRX) | United States | $0.498B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.483B | 14.57 |
| ZimVie (ZIMV) | United States | $0.430B | 39.97 |
| Valneva SE (VALN) | France | $0.425B | 0.00 |
| Jin Medical (ZJYL) | China | $0.422B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.397B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.386B | 0.00 |
| Cerus (CERS) | United States | $0.330B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.325B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.318B | 8.19 |
| Aurora Cannabis (ACB) | Canada | $0.314B | 0.00 |
| Biote (BTMD) | United States | $0.295B | 13.62 |
| Viemed Healthcare (VMD) | United States | $0.281B | 30.17 |
| Zynex (ZYXI) | United States | $0.262B | 45.89 |
| Sanara MedTech (SMTI) | United States | $0.254B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.233B | 15.45 |
| Omeros (OMER) | United States | $0.227B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.192B | 0.00 |
| MacroGenics (MGNX) | United States | $0.191B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.191B | 0.00 |
| High Tide (HITI) | Canada | $0.157B | 65.00 |
| FitLife Brands (FTLF) | United States | $0.152B | 20.55 |
| Brainsway (BWAY) | Israel | $0.137B | 164.20 |
| TriSalus Life Sciences (TLSI) | United States | $0.122B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.122B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.117B | 0.00 |
| Veru (VERU) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.112B | 11.39 |
| Jushi Holdings (JUSHF) | United States | $0.105B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.098B | 24.00 |
| Zevia PBC (ZVIA) | United States | $0.085B | 0.00 |
| InterCure (INCR) | Israel | $0.083B | 14.08 |
| Cytosorbents (CTSO) | United States | $0.077B | 0.00 |
| Modular Medical (MODD) | United States | $0.077B | 0.00 |
| Safety Shot (SHOT) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.068B | 0.00 |
| MariMed (MRMD) | United States | $0.065B | 0.00 |
| Exagen (XGN) | United States | $0.055B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.053B | 3.44 |
| Allurion Technologies (ALUR) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.041B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.026B | 0.00 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.007B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.000B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 21.89 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |